![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Louisiana Floats Subscription-Based Payment Model for Hep C Drugs
Louisiana Floats Subscription-Based Payment Model for Hep C Drugs
![](https://www.fdanews.com/ext/resources/test/Device_Images4/MoneyinHand2.gif?t=1433878512&width=430)
August 10, 2018
The Louisiana Department of Health is considering subscription-based payments for manufacturers of hepatitis C drugs as a way to control the state’s spending on drugs and to serve more Medicaid patients.
Under the proposal, the state would pay flat amounts to drugmakers over a several-year period in exchange for unlimited access to the drugs for anyone enrolled in the state Medicaid program or incarcerated in a state prison.
The department says the plan would cost less than what the state currently spends on hepatitis C drugs for the Medicaid and prison populations. The state paid about $35 million for hepatitis C drugs in 2017.
Upcoming Events
-
21Oct